CD336 (NKp44), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD336 (NKp44), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD336 (NKp44), Human |
| Clone | 2.29 |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | PE-Vio 770 conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD336 (NKp44) Antibody, anti-human, PE-Vio® 770. Clone 2.29 recognizes the CD336 antigen, also known as NKp44. CD336 is a member of the natural cytotoxicity receptor (NCR) family which trigger cytotoxicity in natural killer (NK) cells. CD336 is directly involved in target cell recognition and lysis and is only expressed by activated NK cells, e.g., NK cells cultured in the presence of interleukin 2 (IL-2). Freshly isolated, resting NK cells do not express CD336 (Nkp44). |
| Immunogen | n/a |
| Other Names | NCR2, LY95, NKp44 |
| Gene, Accession # | Gene ID: 9436 |
| Catalog # | 130-120-487 |
| Price | $355 |
| Order / More Info | CD336 (NKp44), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Vitale, M. et al. (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187: 2065-2072. | Moretta, L. and Moretta, A. (2004) Unravelling natural killer function: Triggering and inhibitory human NK receptors. EMBO J. 23: 255-259. | Sivori, S. et al. (2000) 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. 30: 787-793. | Moretta, A. et al. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19: 197-223. | Chaput, N. et al. (2013) Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome. Oncoimmunology 2 (2): e23080. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies